Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral L-citrulline in Steady-State Sickle Cell
NCT02659644Phase 1Withdrawn
- Sponsor
- University of Mississippi Medical Center
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of citrulline in sickle cell disease (SCD), sponsored by University of Mississippi Medical Center. Primary endpoints: Peak plasma citrulline concentration at 7 days, Rate of citrulline appearance at 7 days and 3 more. Planned start Dec 2015; status: withdrawn.
02
Drugs
citrulline
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02659644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659644.